Terms: = Breast cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
171 results:
1. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer.
Abdullah N; Al-Mansouri L; Ali N; Hadi NR
J Med Life; 2023 Nov; 16(11):1633-1638. PubMed ID: 38406785
[TBL] [Abstract] [Full Text] [Related]
3. Primary breast rhabdomyosarcoma in a 17-year-old girl.
Singotia L; Haritha VS
J Cancer Res Ther; 2023 Oct; 19(7):2070-2071. PubMed ID: 38376322
[TBL] [Abstract] [Full Text] [Related]
4. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer.
Liu Y; He X; Yang YI
J Biosci; 2024; 49():. PubMed ID: 38287674
[TBL] [Abstract] [Full Text] [Related]
5. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative breast cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract] [Full Text] [Related]
6. MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive breast cancer.
Chi W; Xiu B; Xiong M; Wang X; Li P; Zhang Q; Hou J; Sang Y; Zhou X; Chen M; Zheng S; Zhang L; Xue J; Chi Y; Wu J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203393
[TBL] [Abstract] [Full Text] [Related]
7. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract] [Full Text] [Related]
9.
Xie Y; Li Y; Yang M
J Immunol Res; 2023; 2023():5041223. PubMed ID: 38125697
[No Abstract] [Full Text] [Related]
10. Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
Chen X; Hu G; Yu Q
Front Endocrinol (Lausanne); 2023; 14():1256132. PubMed ID: 38116315
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
[TBL] [Abstract] [Full Text] [Related]
12. Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer.
Liu G; Zhang T; Gui D; Liu Q
Aging (Albany NY); 2023 Nov; 15(22):13118-13133. PubMed ID: 37988196
[TBL] [Abstract] [Full Text] [Related]
13. CEP55 as a Promising Immune Intervention Marker to Regulate Tumor Progression: A Pan-cancer Analysis with Experimental Verification.
Wang G; Chen B; Su Y; Qu N; Zhou D; Zhou W
Cells; 2023 Oct; 12(20):. PubMed ID: 37887301
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
15. The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer.
Zohair B; Chraa D; Rezouki I; Benthami H; Razzouki I; Elkarroumi M; Olive D; Karkouri M; Badou A
Front Immunol; 2023; 14():1201632. PubMed ID: 37753093
[TBL] [Abstract] [Full Text] [Related]
16. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function.
Funauchi M; Serada S; Hiramatsu K; Funajima E; Kanda M; Nagase Y; Nakagawa S; Ohkawara T; Fujimoto M; Suzuki Y; Ueda Y; Kimura T; Naka T
Int J Cancer; 2024 Feb; 154(3):425-433. PubMed ID: 37728485
[TBL] [Abstract] [Full Text] [Related]
17. Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer.
Zhou Q; Xu J; Xu Y; Sun S; Chen J
Front Immunol; 2023; 14():1176647. PubMed ID: 37671167
[TBL] [Abstract] [Full Text] [Related]
18. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation.
Zhao W; Chang Y; Wu Z; Jiang X; Li Y; Xie R; Fu D; Sun C; Gao J
PeerJ; 2023; 11():e15703. PubMed ID: 37483962
[TBL] [Abstract] [Full Text] [Related]
19. A novel pyroptosis-related signature predicts prognosis and indicates immunotherapy in oral squamous cell carcinoma.
Gao Y; Zhang X; Li Y; Gao J; Liu S; Cai H; Zhang J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12057-12070. PubMed ID: 37421458
[TBL] [Abstract] [Full Text] [Related]
20. Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.
Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
[TBL] [Abstract] [Full Text] [Related]
[Next]
